title: Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
abstract: Little is known about the interaction of novel anticancer drugs with other treatment modalities. THE AIM of this study was to examine the effect of combining imatinib mesylate (STI-571) with radiation or cisplatin on the survival of two human solid tumor cell lines - SKNMC cells derived from Ewing sarcoma and breast cancer MCF-7 cells.
  
  
  METHODS
  Cell proliferation was determined using the sulphorodamine B cytotoxicity assay. Cell cycle analysis was performed with flow cytometry. Apoptosis was determined using a commercial cell death ELISA plus kit. Phosphorylated AKT, which has been suggested to be involved in radiation resistance, was detected by Western blot analysis.
  
  
  RESULTS
  Exposure of SKNMC cells to STI-571 resulted in a dose-dependent antiproliferative effect and a decrease in phosphorylated AKT expression. There was no evidence of apoptosis. The combination of STI-571 with radiation or cisplatin had an additive antiproliferative effect in SKNMC cells (60% reduction in cell number). A similar effect was observed in human MCF-7 breast cancer cells.
  
  
  CONCLUSIONS
  STI-571 improves the outcome of cisplatin or irradiation treatment in vitro. AKT pathway may play a role in the additive effect of STI-571 and irradiation.
authors: Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus Petach Tikva, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel.
authors: R
authors: R
authors: Yerushalmi
authors: J
authors: J
authors: Nordenberg
authors: E
authors: E
authors: Beery
authors: O
authors: O
authors: Uziel
authors: M
authors: M
authors: Lahav
authors: D
authors: D
authors: Luria
authors: E
authors: E
authors: Fenig
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D005456:Fluorescent Dyes / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D066298:In Vitro Techniques; D020128:Inhibitory Concentration 50; D010766:Phosphorylation / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D012235:Rhodamines / Q000378:metabolism; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D005456:Fluorescent Dyes; D010879:Piperazines; D011743:Pyrimidines; D012235:Rhodamines; C022027:lissamine rhodamine B; D000068877:Imatinib Mesylate; D051057:Proto-Oncogene Proteins c-akt; D002945:Cisplatin